PKC-412 CAS: 120685-11-2
MF: C35H30N4O4
MW: 570.64
A broad spectrum tyrosine kinase inhibitor.

PKC-412 (CAS 120685-11-2)

PKC-412 | CAS 120685-11-2 is rated 5.0 out of 5 by 1.
  • y_2020, m_8, d_12, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_200691, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 136ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: Midostaurin; 4'-N-benzoylstaurosporine; PKC412
Application: PKC-412 is a broad spectrum tyrosine kinase inhibitor
CAS Number: 120685-11-2
Purity: ≥96%
Molecular Weight: 570.64
Molecular Formula: C35H30N4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

PKC-412, a staurosporine derivative, has been shown to possess antiproliferative characteristics via inhibition of PKC (protein kinase C), Flk (kinase insert domain receptor), and c-kit. This compound has been shown to cause an increase in the G2/M phase of the cell cycle related to polyploidy, enhanced sensitivity to ionizing radiation, and apoptosis. Additionally, PKC-412 has been reported to inhibit Flt-3/Flk-2 tyrosine kinase which consequentially causes induced G1 arrest and apoptosis of Ba/F3 cell lines. Other experiments have noted that this agent demonstrates the ability to increase endothelial nitric oxide (NO) synthase expression and NO production in cultured human endothelial cells. PKC-412 is an inhibitor of c-Src, Cdk1, cyclin B, EGFR, Flk-1, Flt-1, PDGFR-β, PKA, PKC α, PKC β, PKC γ, PKC δ, PKC η, Fgr and Syk.


References

1. Fabbro, D., et al. 2000. Anticancer Drug Des. 15: 17-28. PMID: 10888033
2. Weisberg, E., et al. 2002. Cancer Cell. 1: 433-443. PMID: 12124173
3. Stone, R.M., et al. 2005. Blood. 105: 54-60. PMID: 15345597
4. Li, H., et al. 2005. Nitric Oxide. 12: 231-236. PMID: 15890550
5. Chen, J., et al. 2005. Oncogene. 24: 8259-8267. PMID: 16091734

Physical State :
Solid
Solubility :
Soluble in DMSO (15 mg/ml), MDC (10 mg/ml), methanol (5 mg/ml), 100% ethanol (2.5 mg/ml), and DMF (20 mg/ml).
Storage :
Store at -20° C
Density :
1.48 g/cm3
Refractive Index :
n20D 1.77
IC50 :
MV4-11 (Myeloid leukemia cells): IC50 = 12 nM (human); FLT3 ITD mutant autophosphorylation: IC50 = 13 nM (human RS4-11 cells); Tyrosine-protein kinase receptor FLT3: IC50 = 15 nM (human)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
9829523
Merck Index :
14: 6185
MDL Number :
MFCD10687105
SMILES :
C[[email protected]@]12[[email protected]@H]([[email protected]@H](C[[email protected]@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)N(C)C(=O)C9=CC=CC=C9)OC

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

PKC-412 (CAS 120685-11-2)  Product Citations

See how others have used PKC-412 (CAS 120685-11-2). Click on the entry to view the PubMed entry .

Citations 1 to 8 of 8 total

PMID: # 28403213  Hara, Y. et al. 2017. PLoS ONE. 12: e0175514.

PMID: # 28506695  Omori, I. et al. 2017. Exp. Hematol. 52: 56-64.e4.

PMID: # 28192400  Obata, Y. et al. 2017. Oncogene. 36: 3661-3672.

PMID: # 26771236  Fox, JM. et al. 2016. Oncotarget. 7: 7268-79.

PMID: # 27543462  Sulen, A. et al. 2016. Pharmacol. Res. 113: 216-227.

PMID: # 26104663  Peng, X. et al. 2015. Leukemia. 29: 2355-65.

PMID: # 24735609  Yoshida, A. et al. 2014. Biochem. Pharmacol. 90: 16-24.

PMID: # 25493654  Obata, Y. et al. 2014. Nat Commun. 5: 5715.

Citations 1 to 8 of 8 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 113ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Chen et al Chen et al. (PubMed ID 16091734) found that treatment of hematopoietic malignancies with the tyrosine kinase inhibitor, PKC-412, prevented the proliferation of hematopoietic Ba/F3 cells via FGFR3 regulation. -SCBT Publication Review
Date published: 2015-06-16
  • y_2020, m_8, d_12, h_15
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_200691, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 20ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.